Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.

US pharma giant Merck & Co opened Tuesday’s trading 10% lower after announcing its annual and fourth quarter financial ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The healthcare pioneer shares insights on transformative diagnostics where precision medicine meets women’s health innovation ...

We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...

In a report released today, Falko Friedrichs from Deutsche Bank maintained a Buy rating on Merck KGaA (0O14 – Research Report), with a price ...

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief ...

Minds + Assembly, a 2024 MM+M Agency 100 honoree, added Chuck Hemann as chief integration officer and Jonathan Woodring as ...

With the overall stock market very overbought, the four highest-yielding Dogs of the Dow look like outstanding ideas now.

Subin Baral, EY global life sciences deals leader, told GEN M&A deals are expected to increase in 2025, driven by biopharmas that are eager to recoup revenues they expect to lose as their aging ...